News & Events

Clinical research and studies demonstrate Gondola AMPS therapy’s effectiveness for people with neurological disease to move better and live better. The CHF 500’000 Tech Growth loan from the Fondation pour l’Innovation Technologique…

Gait disturbances in Parkinson’s disease and parkinsonism, also called parkinsonian gait, worsen the risk of falling and directly impact life quality. Parkinsonian gait is a complex combination of multiple factors. At Gondola…

If you have any questions about the science behind the Gondola AMPS therapy, get in touch with our clinical team. They are happy to discuss academic and clinical research collaborations along with questions about our past and future research. They are passionate about explaining the Gondola AMPS mechanism of action and how the therapy manages to achieve a remarkable clinical effect. Also, any neuroscience questions and interest in the AMPS therapy treatment plan are welcome. The clinical team at Gondola Medical Technologies currently consists of three team members, Shannon Edd, Ph.D., Clinical Research Manager, Tiffany Corbet, PT, Ph.D., and Clinical Field Scientist Paul Alouani, MSc, Clinical Research Associate.

Reduced access to healthcare Since the beginning of the COVID crisis, European countries have adopted unprecedented measures to counter the pandemic. These measures come with significant consequences on society, everyday life, and…

We are happy to announce that Gondola Medical Technologies participates at the SfN Global Connectome: A virtual conference organized by the Society for Neuroscience.